Publication | Closed Access

Rationale for Treatment and Study Design of TAILOR: A Randomized Phase III Trial of Second-line Erlotinib Versus Docetaxel in the Treatment of Patients Affected by Advanced Non–Small-Cell Lung Cancer With the Absence of Epidermal Growth Factor Receptor Mutations

OncologyStudy DesignPatients AffectedMedicineClinical TrialsBronchial NeoplasmCancer TreatmentPharmacologyRadiation OncologyLung CancerMolecular OncologyCancer GrowthHealth Sciences